Catalogue No.
21062323
94-10
94-10
Cell Line Name
94-10
Cell Line Description
Established from a 74 year old male with a transitional cell carcinoma (TCC) in the bladder (Stage T3, Grade II/III). The patient had 2 recurrences and the progression at each recurrence was classified as Stage Ta, Grade I and Stage T1, Grade II).
Also known as TCC 94-10.
General Info
Species
Human
Unique to ECACC
Yes
Also Known As
TCC 94-10
Links
Release Conditions
Characteristics
Products
The line was deposited with a full STR profile from the depositor along with the following cell line mutation data: FGFR31 - p.S249C*, PIK3CA - p.V136I, PIK3R1 - WT, TP53 - WT, RAS - WT, TSC1 - WT, AKT1 - WT, STAG2 - splice site; c.2097-2A>G, TERT promoter - -124 bp G>A, CDKN2A copy number - Unknown. * Amino acid positions are numbered relative to the FGFR3 IIIb isoform.
Tissue of Origin
Bladder
Disease
Transitional cell carcinoma
Culture Conditions
Subculture Routine
Incubation at 37oC with 5% CO2.
Split sub-confluent log-phase cultures with 0.05% Trypsin/EDTA solution. Note: cells can take more than 15 minutes to fully detach from the plastic. Neutralise trypsin/EDTA solution with media containing 10% Foetal Bovine serum (FBS) or Soya bean trypsin inhibitor (SBTI) solution at ratio of 1:10, for low serum cultures.
Establish new cultures at 1-4 x 104 cells per cm2.
Cell lines are relatively slow growing under these culture conditions.
Cryopreserve cells in growth medium containing 10% DMSO.
Culture Medium
Hams F12 + 1% FBS + 1x Insulin-Transferrin-Selenium + 1μg/ml hydrocortisone + 1x Non-essential amino acids 100x + 2mM L-Glutamine.
Growth Mode
Adherent
Additional Info
Depositor
Deposited by Margaret Knowles at the Division of Molecular Medicine, Leeds Institute of Medical Research at St James’s, St James's University Hospital, Beckett Street, Leeds LS9 7TF. Deposited on behalf of Dr Catherine Reznikoff Departments of Human Oncology, University of Wisconsin Comprehensive Cancer Centre and University of Wisconsin Medical School.
Country of Origin
United States
Hazard Group (ACDP)
Hazard Group (ACDP) 2
Applications
References
Yeager, T R et al. “Overcoming cellular senescence in human cancer pathogenesis.” Genes & development vol. 12,2 (1998): 163-74. doi:10.1101/gad.12.2.163 PMID: 9436977
Bibliography
Taylor, Claire F et al. “Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes.” Human molecular genetics vol. 23,8 (2014): 1964-74. doi:10.1093/hmg/ddt589 PMID: 24270882
Platt, Fiona M et al. “Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 15,19 (2009): 6008-17. doi:10.1158/1078-0432.CCR-09-0898 PMID: 19789314
Hurst, Carolyn D et al. “Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.” European urology vol. 65,2 (2014): 367-9. doi:10.1016/j.eururo.2013.08.057 PMID: 24035680
Jebar, Adel H et al. “FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.” Oncogene vol. 24,33 (2005): 5218-25. doi:10.1038/sj.onc.1208705 PMID: 15897885
Ross, Rebecca L et al. “Identification of mutations in distinct regions of p85 alpha in urothelial cancer.” PloS one vol. 8,12 e84411. 18 Dec. 2013, doi:10.1371/journal.pone.0084411 PMID: 24367658
Askham, J M et al. “AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.” Oncogene vol. 29,1 (2010): 150-5. doi:10.1038/onc.2009.315 PMID: 19802009
Available Formats
- Frozen
- DNA-5µg (100ng/µl)
Citation Guidance
If use of this culture results in a scientific publication, it should be cited in the publication as: 94-10 (ECACC 21062323).
Biosafety Information
Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Further Information
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.